one-sided / two-sided [General Sta­tis­tics]

posted by ElMaestro  – Belgium?, 2019-03-04 09:04  – Posting: # 19997
Views: 1,457

Hi Hötzi,

» In other words, if patients are treated with the originator’s product, there is a 5% risk that it does not perform better (more efficient and/or safer) than placebo.

There is no more than a 5% risk of approving the test product (=concluding superiority) if the test product is not superior.

» If we would test for BE at the 2.5% level (95% CI) we would be overly strict and at the same time gain absolutely nothing in terms of the patient’s risk.

The patient's risk would be halved (max 2.5% chance of approving a non-BE product; CIs would get wider).

Le tits now.

Best regards,

Complete thread:

 Admin contact
20,237 posts in 4,258 threads, 1,396 registered users;
online 8 (0 registered, 8 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 16:50 CET

Science may set limits to knowledge,
but should not set limits to imagination.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz